Suchen Sie nach Informationen zu Retrophin-Hauptquartier? Folgen Sie den Links unten, um alle Informationen zu finden, die Sie benötigen, und mehr.
https://ir.travere.com/news-releases/news-release-details/retrophin-announces-corporate-name-change-travere-therapeutics
Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on November 19. SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Retrophin Inc., (NASDAQ: RTRX) today announced that the Company has changed its global corporate name to Travere Therapeutics, Inc. This new name reflects the Company’s steadfast dedication to helping people as they …
https://www.indeed.com/cmp/Retrophin
Find out what works well at Retrophin from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles and read about the team’s work-life balance. Uncover why Retrophin is the best company for you.
https://www.zippia.com/retrophin-careers-9811/
Retrophin is a medium health care company with 262 employees and an annual revenue of $198.3M that is headquartered in San Diego, CA. To deliver life-changing therapies to people living with rare diseases, who have few, if any, treatment options. Retrophin provides a comprehensive benefits package to employees which include insurance plans ...
https://travere.com/news/retrophin-announces-name-change/
SAN DIEGO, November 16, 2020 – Retrophin Inc., (NASDAQ: RTRX) today announced that the company has changed its global corporate name to Travere Therapeutics, Inc. Read the press release >. PATHFINDER.
https://www.globenewswire.com/news-release/2020/11/16/2127259/0/en/Retrophin-Announces-Corporate-Name-Change-to-Travere-Therapeutics-Inc.html
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Retrophin Inc., (NASDAQ: RTRX) today announced that the Company has changed its global corporate name to Travere Therapeutics, Inc. This new name ...
https://www.wsj.com/articles/retrophin-founded-by-martin-shkreli-rebrands-itself-as-travere-therapeutics-11605531600
Retrophin a biopharmaceutical company founded by now-convicted drug executive Martin Shkreli, is rebranding itself as Travere Therapeutics Inc. The new name—which company officials say is a nod ...
https://ir.travere.com/news-releases/news-release-details/retrophin-completes-acquisition-orphan-technologies
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN ...
https://www.indeed.com/cmp/Retrophin/reviews
retrophin. Clinical Account Manager (Former Employee) - St. Louis, MO - October 15, 2018. my favorite company, excellent senior management, great field resources, high caliber sales people, great products. the culture was authentic, hardest [part of the job was the travel, most enjoyable part were the people.
http://www.littlebear.us/retrophin_article_2/
Bottom line – there’s lots of value to be unlocked here. When I look at Retrophin’s existing stable of marketed drugs, it’s no stretch of the imagination to see these franchises throwing off a combined $40 to $50 million in 2015. That would equate to upwards of $1.75 per share in earnings power.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).
Wir hoffen, dass Sie über die obigen Links alle notwendigen Informationen zu Retrophin-Hauptquartier gefunden haben.
